Smallpox vaccines: Current and future

Journal of Laboratory and Clinical Medicine

Volumn 142, Issue 4, 2003, Pages 252-257

  Bonilla Guerrero, Ruben ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALLPOX VACCINE; UNCLASSIFIED DRUG;

CHILL; CLINICAL TRIAL; DRUG DESIGN; ENCEPHALITIS; ERYTHEMA MULTIFORME; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNE SYSTEM; KERATITIS; MOLECULAR DYNAMICS; MYALGIA; PERICARDITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RASH; REVIEW; SIDE EFFECT; SMALLPOX; VACCINIA; WORLD HEALTH ORGANIZATION;

EID: 0344549578     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00143-4     Document Type: Review

References (47)

1. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002;8:1019-28.
2. Henderson DA. The looming threat of bioterrorism. Science 1999;283:1279-82.
3. Esposito J, Fenner F. Poxviruses, in: Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001, p 2885-91.
4. Moss B. Poxviridae: The Viruses and Their Replication, in: Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001, p 2849-83.
5. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva, Switzerland: World Health Organization; 1988.
6. Fenner F. A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis 1982;4:916-30.
7. World Health Organization. Declaration of global eradication of smallpox. Wkly Epidemiol Rec 1980;55:148.
8. Deria A, Jezek Z, Markvart K, Carrasco P, Weisfeld J. The world's last endemic case of smallpox: surveillance and containment measures. Bull World Health Org 1980;58:279-83.
9. Wade N. New smallpox case seems lab-caused. Science 1978; 201:893.
10. Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002;346:1265-74.
11. Frey SE, Newman FK, Cruz J, et al. Dose-related effects of smallpox vaccine. N Engl J Med 2002;346:1275-80.
12. Newman FK, Frey SE, Blevins P, Yan L, Belshe RB. Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax. J Infect Dis 2003;187:1319-22.
13. Frey SE, Newman FK, Yan L, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003; 289:3295-9.
14. Engler RJ, Kenner J, Leung DY. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002;110:357-65.
15. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969;281:1201-8.
16. Fenner F, Henderson DA, Arita I, Ladnyi ID. Developments in vaccination and control between 1900 and 1966. Smallpox and its eradication. Geneva, Switzerland: World Health Organization; 1988:277-312.
17. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002;5: 84-90.
18. Avenus Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to US [press release]. Swiftwater, Pa: Aventis-Pasteur USA; March 29, 2002: www.us.aventispasteur.com/ press_releases/Corporate_News.htm. Accessed June 2003.
19. Bartlett J, Borio L, Radonovich L, Mair JS, O'Toole T, Mair M. Smallpox vaccination in 2003: key information for clinicians. Clin Infect Dis 2003;36:883-902.
20. Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL. Developing new smallpox vaccines. Emerg Infect Dis 2001;7: 920-6.
21. Smallpox vaccine USP [package insert]. Swiftwater, Pa: Connaught Laboratories; March 1976.
22. Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recom Rep 2003;52(RR-7):1-16.
23. Vaccinia (smallpox) vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2001;50(RR-10):1-22.
24. Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recom Rep 2003; 52(RR-4):1-28.
25. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. The pathogenesis, pathology and immunology of smallpox and vaccinia. Smallpox and its eradication. Geneva, Switzerland: World Health Organization; 1988:122-67.
26. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox vaccine and vaccination in the intensified smallpox eradication programme. Smallpox and its eradication. Geneva, Switzerland: World Health Organization; 1988:540-90.
27. VaxGen and Kaketsuken announce agreement to make potentially safer smallpox vaccine for US [press release]. www.vaxgen.com/ pressroom/index.html. Accessed September 18, 2003.
28. Gurvich EB. The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine. Vaccine 1992;10: 96-7.
29. Bray M, Wright ME. Progressive vaccinia. Clin Infect Dis 2003; 36:766-74.
30. Centers for Disease Control and Prevention. Update: adverse events following smallpox vaccination - United States, 2003. JAMA 2003;289:2060-3.
31. Centers for Disease Control and Prevention. Cardiac adverse events following smallpox vaccination - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:248-50.
32. Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003;289:3283-9.
33. Centers for Disease Control and Prevention. Smallpox (vaccinia) vaccine contraindications. http://www.bt.cdc.gov/agent/smallpox/ vaccination/ contraindications-clinic.asp. Accessed June 2003.
34. Centers for Disease Control and Prevention. Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices. JAMA 2003;289: 2064.
35. Update: adverse events following smallpox vaccination - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:278-82.
36. Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346:1300-8.
37. Drexler I, Staib C, Kastenmuller W, et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A 2003;100:217-22.
38. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998;79(pt 5):1159-67.
39. McClain DJ, Harrison S, Yeager CL, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis 1997;175:756-63.
40. Schijns VE. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 2003;21:829-31.
41. Poland GA. Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes. Vaccine 1999;17: 1719-25.
42. Kedl RM, Kappler JW, Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol 2003; 15:120-7.
43. Franco A, Tilly DA, Gramaglia I, Croft M, Cipolla L, Meldal M. Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat Immunol 2000;1:145-50.
44. Terajima M, Cruz J, Raines G, et al. Quantitation of CDS8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003;197:927-32.
45. Poland GA, Ovsyannikova IG, Johnson KL, Naylor S. The role of mass spectrometry in vaccine development. Vaccine 2001;19: 2692-700.
46. Griffin TJ, Aebersold R. Advances in proteome analysis by mass spectrometry. J Biol Chem 2001;276:45497-500.
47. Bakhtiar R, Nelson RW. Mass spectrometry of the proteome. Mol Pharmacol 2001;60:405-15.